A Phase Ib/II, Multi-center, Study of Oral LGH447 in Combination With Oral BYL719 in Patients With Relapsed and Refractory Multiple Myeloma
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 4
- 主要终点
- Phase Ib: Number of Total Dose-limiting Toxicities (DLT)
研究概览
简要总结
This is a Phase Ib/II study with the primary purpose of the Phase Ib part being to estimate the MTD and/or recommended phase 2 dose (RP2D) of the combination of LGH447 and BYL719 when administered orally to adult patients with relapsed and refractory multiple myeloma. Once the MTD and/or RP2D is determined for the combination of LGH447 and BYL719, additional patients will be enrolled in the Phase II part to determine whether the combination of LGH447 and BYL719 exhibits improved anti-multiple myeloma activity compared to single agent LGH447. This trial never made it to the Phase II part of the this trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- •Patients with a confirmed diagnosis of multiple myeloma who have received two or more lines of therapy and are refractory to their most recent line of therapy, as defined as relapse while on therapy or within 60 days from their last line of therapy. If patient has not received either an immunomodulatory drug (IMID) or proteasome inhibitor as a prior therapy then Investigator must notify Novartis prior to the patient enrollment. Patients who have received a prior bone marrow transplant and otherwise meet the inclusion criteria are eligible for this study
- •For patients in the Phase II portion of the study, must have measurable disease defined by at least 1 of the following 3 measurements:
- •Serum M-protein ≥ 0.5 g/dL
- •Urine M-protein ≥ 200 mg/24 hours OR
- •Serum free light chain (FLC) > 100 mg/L of involved FLC
- •All patients must be willing to undergo a mandatory bone marrow aspirate and/or biopsy at baseline for the assessment of biomarker/pharmacodynamics and disease status
排除标准
- •Systemic antineoplastic therapy (including unconjugated therapeutic antibodies and toxin immunoconjugates) or any experimental therapy within 14 days or 5 half-lives, whichever is shorter, before the first dose of either study drug
- •Radiotherapy within 14 days before the first dose of either study drug except localized radiation therapy for lytic bone lesions and plasmacytomas
- •Major surgery within 2 weeks before the first dose of either study drug
- •Ongoing therapy with chronic or high dose corticosteroids. Low dose steroids (i.e. prednisone ≤ 10 mg or an equivalent steroid dose), inhaled and topical steroids are permitted
- •Patients who are currently receiving treatment with a prohibited medication that cannot be discontinued at least one week prior to the start of treatment:
- •Narrow Therapeutic index substrates, strong inhibitors and strong inducers of CYP3A4
- •Strong Inhibitors of CYP2D6
- •Narrow therapeutic index substrates of CYP2C8, CYP2C9, CYP2C19 and CYP2D6
- •Any of the following clinical laboratory results during screening (i.e., within 28 days before the first dose of either study drug):
- •Absolute neutrophil count (ANC) < 1,000/mm3 without growth factor support within 7 days prior to testing
- •Platelet count < 75,000 mm3 without transfusion support within 7 days prior to testing
- •Bilirubin > 1.5 times the upper limit of the normal range (ULN).
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the ULN.
- •Calculated creatinine clearance < 30 ml/min according to Cockcroft-Gault equation
- •Corrected QT interval (QTc) of > 450 milliseconds (ms) in males and > 470 milliseconds (ms) in females on baseline electrocardiogram (ECG) (using Fridericia [QTcF] corrected QT interval
研究组 & 干预措施
Phase Ib: LGH447 + BYL719
Dose-escalation, LGH447 in combinatinon with BYL719
干预措施: LGH447 (Drug)
Phase Ib: LGH447 + BYL719
Dose-escalation, LGH447 in combinatinon with BYL719
干预措施: BYL719 (Drug)
Phase II: LGH447 + BYL719
LGH447 + BYL719 (dosing according to MTD/RP2D from Phase Ib portion of the study)
干预措施: LGH447 (Drug)
Phase II: LGH447 + BYL719
LGH447 + BYL719 (dosing according to MTD/RP2D from Phase Ib portion of the study)
干预措施: BYL719 (Drug)
Phase II: LGH447 alone
LGH447 alone (dosing according to single-agent RDE)
干预措施: LGH447 (Drug)
结局指标
主要结局
Phase Ib: Number of Total Dose-limiting Toxicities (DLT)
时间窗: Cycle 1 (28 days)
Using a Bayesian logistic regression model (BLRM) to guide dose escalation and predict MTD or determine the RP2D for LGH447 in combination with BYL719 in relapsed and refractory multiple myeloma. The frequency and characteristics of DLTs will be assessed.
Phase II: Overall Response Rate (ORR) as assessed by Investigators
时间窗: 29 months (End of Study)
The proportion of patients with a confirmed best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as assessed by Investigators using the International Myeloma Working group (IMWG) Criteria with modifications. End of Study (defined as the time when all patients have completed at least 6 cycles of treatment or discontinued treatment, or have been lost to follow up, whichever occurs first.
次要结局
- Number of participants with adverse events, serious adverse events, changes in laboratory values, and electrocardiograms (ECGs), as a measure of safety and tolerability.(23 months)
- Changes between pre- and post-treatment levels of pS6RP and 4EBP1 levels in bone marrow aspirates and 4EBP1 in peripheral blood(baseline, Cycle 2 Day 1)
- Disease Control Rate(29 months (End of Study))
- Progression Free Survival(29 months (End of Study))
- Time to response(29 months (End of Study))
- Phase II: Percent change of ORR (Overall Response Rate) between the two arms(29 months (End of Study))
- Determine single and multiple dose Pharmacokinetics (PK) profiles(Approximately 8 months)
- Phase II: Absolute difference in ORR(29 months (End of Study))
- Duration of Response(29 months (End of Study))